IL-17

TNF (Tumor Necrosis Factor) is a pleiotropic cytokine with leading role in disease pathogenesis and therefore is a very attractive target for the treatment of a diverse array of diseases, including autoimmunity, cancer, infectious diseases, and graft-versus-host disease.

Date:

Category:

TNF as a therapeutic target

TNF inhibitors/blockers, include biologics and small molecule inhibitors that target diseases like rheumatoid arthritis (RA), juvenile arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, ulcerative colitis (UC), and Crohn’s disease. Several blockers, innovator compounds as well as biosimilars, are currently available in the market including Adalimumab (Humira), Adalimumab-atto (Amjevita), a biosimilar to Humira, Certolizumab pegol (Cimzia), Etanercept (Enbrel), Etanercept-szzs (Ereizi), a biosimilar to Enbrel, Golimumab (Simponi, Simponi Aria), Infliximab (Remicade), Infliximab-dyyb (Inflectra), a biosimilar to Remicade. A continuing interest in the field of TNF blockade is reflected in current efforts to develop next generation anti-TNF therapeutics.

Preclinical Platforms for the evaluation of TNF targeting therapeutics

d
Tg197

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

m
Tg197hTNFR1Kl

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

v
Tg5453

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

d
Tg3647

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

d
TNFΔARE/+

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

d
CAIA

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

d
DSS-induced Colitis

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

d
LPS

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

d
LPS/GaIN

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.